Who are Ketofol 1:3 ratio's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DXM + Propofol, Haloperidol + Ketamine, Lidocaine/Magnesium, Triamcinolone + Lidocaine, Remifentanil, Propofol, and Desflurane, Dexamethasone+ Bupivacaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketofol-1-3-ratio.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ketofol 1:3 ratio — Competitive Intelligence Brief

Ketofol 1:3 ratio (Ketofol 1:3 ratio) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic combination. Area: Anesthesia.

marketed Anesthetic combination NMDA receptor (ketamine); GABA-A receptor (propofol) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Ketofol 1:3 ratio (Ketofol 1:3 ratio) — Kasr El Aini Hospital. Ketofol is a fixed-ratio combination of ketamine and propofol that produces rapid sedation and anesthesia through dual action on NMDA receptors and GABA-A receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ketofol 1:3 ratio TARGET	Ketofol 1:3 ratio	Kasr El Aini Hospital	marketed	Anesthetic combination	NMDA receptor (ketamine); GABA-A receptor (propofol)
DXM + Propofol	DXM + Propofol	Seoul National University Hospital	marketed	Dissociative anesthetic combination	NMDA receptor (DXM); GABA-A receptor (propofol)
Haloperidol + Ketamine	Haloperidol + Ketamine	University Hospital, Basel, Switzerland	marketed	Antipsychotic + Dissociative anesthetic combination	Dopamine D2 receptor (haloperidol); NMDA glutamate receptor (ketamine)
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Triamcinolone + Lidocaine	Triamcinolone + Lidocaine	MetroHealth Medical Center	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (triamcinolone); voltage-gated sodium channels (lidocaine)
Remifentanil, Propofol, and Desflurane	Remifentanil, Propofol, and Desflurane	The Cooper Health System	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane)
Dexamethasone+ Bupivacaine	Dexamethasone+ Bupivacaine	Ain Shams University	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic combination class)

Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
Kasr El Aini Hospital · 1 drug in this class
Universidad de Cartagena · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketofol 1:3 ratio — Competitive Intelligence Brief. https://druglandscape.com/ci/ketofol-1-3-ratio. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab